Floatz logo

Nivolumab

Neoplasm With Perivascular Epithelioid Cell Differentiation

Sarcoma Oncology Research Center, LLCmonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Neoplasm With Perivascular Epithelioid Cell Differentiation cohort.

Asset / SponsorPhaseRating
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Nab-Rapamycin
Sarcoma Oncology Research Center, LLC
Phase 1/2CCC
Dactolisib
Novartis Pharmaceuticals
Phase 2CCC
Ivocizumab
Fudan University
Phase 2NR

Same molecule, other indications

Nivolumab is also rated in:

renal carcinomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →
metastatic melanomaActive
BB
Indicative · Phase 4
70 / 100
View asset →
non-small cell lung carcinomaActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →